NEW YORK, January 16, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Express Scripts Inc. (NASDAQ: ESRX), Agilent Technologies Inc. (NYSE: A), Quest Diagnostics Inc. (NYSE: DGX), Covidien plc (NYSE: COV), and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Express Scripts Inc. Research Report
On January 13, 2014, Express Scripts Inc.'s (Express Scripts) stock declined 0.33%, ending the day at $72.62. Over the previous three trading sessions, shares of Express Scripts rose 2.24%, compared to the Nasdaq Composite which declined 1.26% during the same period. The Full Research Report on Express Scripts Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Agilent Technologies Inc. Research Report
On January 13, 2014, Agilent Technologies Inc. (Agilent) reported that it has provided a grant to the newly set up Duke Molecular Physiology Institute (DMPI). The Company stated that the DMPI research team is utilizing Agilent's integrated biology solutions to better understand the metabolic and physiologic aspects of major chronic diseases like cardiovascular disease. Dr. Christopher Newgard, Head of DMPI and Professor at Duke University School of Medicine's Department of Pharmacology and Cancer Biology commented, "The Duke Molecular Physiology Institute seeks to combine strong genomics, epigenomics, transcriptomics and metabolomics platforms with computational biology, clinical translation and basic science expertise to gain new insights into the mechanisms of cardiometabolic diseases. We thank Agilent for supporting our research and look forward to collaborating to advance the understanding of cardiovascular and undiagnosed metabolic diseases." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Quest Diagnostics Inc. Research Report
On January 13, 2014, Quest Diagnostics Inc. (Quest Diagnostics) announced that its Board of Directors has appointed Timothy L. Main as a director, with immediate effect. The Company stated that with the addition of Main, the Board now comprises of 10 members. Quest Diagnostics added that Tim Main currently serves as Chairman of the Board of Directors for Jabil Circuit, Inc. Steve Rusckowski, President and CEO, Quest Diagnostics, commented, "Tim has an exceptional record of generating business growth and shareholder value in a competitive, complex global market. This experience, coupled with his deep understanding of operations and supply chain management, will enable him to share a fresh, compelling perspective on Quest as we execute our strategy to restore growth, drive operational excellence and deliver disciplined capital deployment." The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Covidien plc Research Report
On January 13, 2014, Covidien plc (Covidien) reported that the Company has completed two transactions, one in Brazil and the other in China, in order to better meet the specific needs of underserved 'value segment' markets, which includes hospitals that mainly serve patients facing care affordability challenges. The Company informed that it has acquired WEM Equipamentos Eletrônicos Ltda. in Brazil, and in China, it has entered into a joint venture with the Changzhou Kangdi Medical Stapler Co., Ltd. According to Covidien, total impact of these transactions on the Company's revenue and earnings for 2014 is expected to be minimal. Brian King, President, Emerging Markets, Covidien, commented, "By combining Covidien's proven business model with the capabilities of our new partners, we'll be able to scale the value segment opportunity and help provide more affordable healthcare solutions in new markets." The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Sanofi Research Report
On January 13, 2014, Sanofi's stock declined 1.54%, ending the day at $50.03. Over the previous three trading sessions, shares of Sanofi fell 2.06%, compared to the Dow Jones Industrial Average which declined 1.24% during the same period. The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner